- Press releases
Asceneuron SA, an emerging leader in the development of innovative small molecules targeting tauopathies such as progressive supranuclear palsy (PSP), Alzheimer’s disease and related neurodegenerative diseases, today announced the appointment of Hans Schikan (PharmD) as Non-Executive Chairman to the Board of Directors.
“We are extremely pleased to welcome Hans Schikan as Chairman to our Board of Directors in recognition of the rapid progress the company has made in the development of drug candidates for rare tauopathies which is supported by our recent CHF 30 million Series A financing round” said Dirk Beher (PhD), Chief Executive Officer and a Founder of Asceneuron. “Hans’ vast orphan drug development expertise will help us tremendously in moving this company toward our ultimate goal to bring new medicines to patients and their families.”
Hans Schikan is former Chief Executive Officer of Prosensa, a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases like Duchenne muscular dystrophy. Prosensa was listed on NASDAQ (RNA) since June 2013. The company was acquired by BioMarin early 2015 for up to USD 840 million. Before joining Prosensa, Hans worked at Genzyme, including as Vice President for Global Marketing and Strategic Development of Genzyme’s product portfolio for rare genetic diseases. Prior to Genzyme, he worked at Organon, both at corporate level and in country operations which included assignments in Asia and Europe. Hans is currently Chairman of the Board of Complix (Belgium) and InteRNA Technologies (Netherlands). In addition, he is Board Member of Hansa Medical, Sobi and Wilson Therapeutics (Sweden). He is also Member of the Top Team of the Dutch Top Sector Life Sciences & Health and Adviser of Khondrion (Netherlands).
“I am delighted to join Asceneuron at this exciting time in the company’s development, with solid science, a promising pipeline, a great team and a strong syndicate of investors” said Hans Schikan. “I look forward to adding my experience and helping the team to develop its products in progressive supranuclear palsy (PSP), Alzheimer’s disease and related neurodegenerative diseases, which represent a huge medical need.”
Asceneuron researches and develops oral small molecule therapeutics targeting tauopathies for treating progressive supranuclear palsy (PSP), other related neurodegenerative diseases and Alzheimer’s disease. The lead product, an O-GlcNAcase inhibitor that in preclinical studies has been demonstrated to modulate tau pathology, has entered the critical regulatory studies to allow its entry into human clinical testing. Neuronal deposits of the microtubule-associated tau protein are a common feature of tauopathies and known to be a major contributor to neurodegenerative diseases. Asceneuron was founded in 2012. Investors include Sofinnova Partners, SR One, Kurma Partners, Johnson & Johnson Innovation – JJDC, Inc. and founding investor MS Ventures, the strategic corporate venture capital fund of the healthcare business of Merck. For more information, please visit www.asceneuron.com.